Caption Management LLC Invests $1.74 Million in ICU Medical, Inc. $ICUI

Key Points

• Caption Management LLC has acquired a new position in ICU Medical, purchasing 12,510 shares valued at approximately $1,737,000, representing about 0.05% of the company.
• A number of institutional investors have significantly increased their stakes in ICU Medical, with Quarry LP boosting its stake by 764.3% during the last quarter.
• ICU Medical reported a quarterly EPS of $2.10, exceeding the consensus estimate of $1.44, and has a projected FY 2025 EPS guidance of 6.850-7.15.

Caption Management LLC acquired a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 12,510 shares of the medical instruments supplier's stock, valued at approximately $1,737,000. Caption Management LLC owned about 0.05% of ICU Medical as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in ICUI. Tower Research Capital LLC TRC boosted its holdings in shares of ICU Medical by 87.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,352 shares of the medical instruments supplier's stock worth $210,000 after purchasing an additional 632 shares during the last quarter. Hsbc Holdings PLC boosted its holdings in shares of ICU Medical by 12.1% during the fourth quarter. Hsbc Holdings PLC now owns 5,707 shares of the medical instruments supplier's stock worth $886,000 after purchasing an additional 618 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of ICU Medical by 17.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 17,772 shares of the medical instruments supplier's stock worth $2,758,000 after purchasing an additional 2,578 shares during the last quarter. Quarry LP boosted its holdings in shares of ICU Medical by 764.3% during the fourth quarter. Quarry LP now owns 242 shares of the medical instruments supplier's stock worth $38,000 after purchasing an additional 214 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of ICU Medical by 11.1% during the fourth quarter. Northern Trust Corp now owns 402,342 shares of the medical instruments supplier's stock worth $62,431,000 after purchasing an additional 40,187 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company's stock.

Insider Activity

In other ICU Medical news, CEO Vivek Jain bought 21,929 shares of the company's stock in a transaction dated Thursday, August 14th. The shares were acquired at an average cost of $112.84 per share, with a total value of $2,474,468.36. Following the completion of the transaction, the chief executive officer owned 130,149 shares in the company, valued at $14,686,013.16. The trade was a 20.26% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David C. Greenberg bought 1,200 shares of the company's stock in a transaction dated Wednesday, August 27th. The shares were acquired at an average cost of $126.42 per share, for a total transaction of $151,704.00. Following the completion of the transaction, the director owned 7,960 shares of the company's stock, valued at approximately $1,006,303.20. The trade was a 17.75% increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Piper Sandler began coverage on ICU Medical in a report on Friday, August 15th. They issued an "overweight" rating and a $145.00 target price on the stock. Wall Street Zen raised ICU Medical from a "hold" rating to a "buy" rating in a research report on Friday. Finally, Raymond James Financial lowered their price target on ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating for the company in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, ICU Medical presently has a consensus rating of "Buy" and an average price target of $179.00.

ICU Medical Stock Up 4.5%

NASDAQ:ICUI traded up $5.61 during mid-day trading on Friday, hitting $131.24. The company had a trading volume of 280,702 shares, compared to its average volume of 376,226. The business has a fifty day simple moving average of $126.51 and a 200-day simple moving average of $134.81. The company has a current ratio of 2.44, a quick ratio of 1.17 and a debt-to-equity ratio of 0.63. ICU Medical, Inc. has a 1 year low of $107.00 and a 1 year high of $196.26. The firm has a market capitalization of $3.24 billion, a price-to-earnings ratio of -86.34 and a beta of 0.86.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $2.10 EPS for the quarter, beating the consensus estimate of $1.44 by $0.66. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The company had revenue of $543.57 million for the quarter, compared to analyst estimates of $543.33 million. During the same period last year, the company posted $1.56 earnings per share. The firm's revenue was down 8.0% compared to the same quarter last year. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. Equities analysts forecast that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.